Adipose stem cell exosome nasal drops for mild to moderate Alzheimer's disease
Phase I/II trial, General Psychiatry, 2023 (NCT04388982)
Improvement reported, no control group
Improvement reported, no control group: Patients improved, but without a comparison group there is no way to tell whether the treatment caused it.
Level 2 of 5: A group was treated and followed, but nobody was left untreated for comparison. Improvement may come from time, other care, or the placebo effect.
See the full key- Design
- Open-label, single-center, three dose groups
- People
- 9 planned in the registry
- Made from
- Fat (adipose) stem cells
- How it was given
- Nasal drops twice a week for 12 weeks
What they found
No adverse events. In the medium-dose group, cognitive test scores improved compared with baseline at 12 weeks. Amyloid and tau deposits did not differ between dose groups.
What limits it
No placebo group, so cognitive changes are compared only with each patient's own starting point. Very small.